VIJAYA DIAGNOSTIC CENTRE®

November 03, 2026

The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on Tuesday, November 03, 2026

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today *i.e.,* Tuesday, November 03, 2026, has *inter-alia* considered and approved the following:

1. Unaudited Financial Results of the Company for the second quarter ended September 30, 2026

In terms of the above, we enclose herewith the following:

a) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026; and
b) Limited review Reports on the Standalone & Consolidated Financial Results for quarter and half year ended September 30, 2026.

2. Appointment of Mr. Rahul Jain as a Company Secretary and Compliance officer (Key Managerial Personnel) of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board has appointed Mr. Rahul Jain (Membership No. ACS A62949) as Company Secretary and Compliance Officer pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from November 03, 2026.

Details with respect to Change in Key Managerial Personnel (Appointment of Company Secretary and Compliance Officer) as required under Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations and read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended is provided in **Annexure A.**

VIJAYA DIAGNOSTIC CENTRE®

The Board Meeting commenced at 06 :12 P.M. (IST) and concluded at 06:40 P.M.(IST).

Kindly take the same on record.

Thanking You.

Yours faithfully,

For **Vijaya Diagnostic Centre Limited**

KOLUKULURI APPALA NARASIMHA RAJU

Digitally signed by KOLUKULURI APPALA NARASIMHA RAJU

Narasimha Raju K A

Chief Financial Officer

Encl.: As above

VIJAYA DIAGNOSTIC CENTRE®

ANNEXURE A

Particulars required as per Regulation 30 of SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 read with SEBI Circular No. HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated 30th January, 2026 are given below;

Sr. No.	Details of events that need to be provided	Information of such event
1.	Reason for Change viz. appointment, ~~resignation, removal, death or otherwise;~~	Appointment of Mr. Rahul Jain, as the Company Secretary and Compliance Officer designated as Key Managerial Personnel of the Company.
2.	Date of Appointment/Cessation & term of Appointment/ ~~Re-appointment~~;	November 3, 2026
3.	Brief profile (in case of appointment);	**Mr. Rahul Jain** is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). He has over six years of professional experience in the field of corporate secretarial functions, Corporate Governance and regulatory compliances, with extensive exposure to the regulatory framework applicable to listed companies. His areas of expertise include the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI (Prohibition of Insider Trading) Regulations, 2015, SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, FEMA and other applicable regulatory requirements. He has experience in managing Board and shareholders' meetings, corporate restructuring, preferential allotments, FCCB issuances, ESOPs, share capital restructuring, regulatory disclosures, stock exchange compliances and corporate governance matters.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The Company has accounted for the amalgamation of Medinova Diagnostic Services Limited ("transferor company") with the Company during the quarter and half year ended 30 September 2025 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025. The amalgamation has been accounted for by the Company by restating the financial information in the financial results in respect of the prior periods as if it had occurred from the beginning of the preceding year in the financial statements as per the requirement of Indian Accounting Standard.

   The corresponding figures for the quarter and half year ended 30 September 2025, in so far it pertains to the transferor company, have been reviewed by another auditor who had expressed an unmodified conclusion on 3 November 2025.

Limited Review Report *(Continued)*

Vijaya Diagnostic Centre Limited

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHAN KABRA

Digitally signed by BALKISHAN KABRA
Date: 2026.11.03 19:25:49 +05'30'

Balkishan Kabra

Partner

Membership No.: 221202

UDIN:26221202ZVJHDX2625

Hyderabad

03 November 2026

Vijaya Diagnsotic Centre Limited
CIN: L85195TG2002PLC039075
Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 30 September 2026

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited (Refer Note 6)	Unaudited	Unaudited (Refer Note 6)	Audited (Refer Note 6)
1	**Income**						
	(a) Revenue from operations	24,200.20	21,853.71	18,996.41	46,053.91	36,733.24	76,779.09
	(b) Other income	544.91	902.01	517.04	1,446.92	1,243.12	2,524.15
	Total income	**24,745.11**	**22,755.72**	**19,513.45**	**47,500.83**	**37,976.36**	**79,303.24**
2	**Expenses**						
	(a) Cost of materials consumed	2,722.36	2,431.75	2,266.77	5,154.11	4,285.61	8,950.43
	(b) Employee benefits expense	3,597.96	3,489.58	2,997.87	7,087.54	5,944.73	12,154.51
	(c) Finance costs	1,082.13	1,041.78	721.41	2,123.91	1,412.70	3,082.59
	(d) Depreciation and amortisation expense	2,398.80	2,232.73	1,939.72	4,631.53	3,775.92	8,042.68
	(e) Other expenses	7,151.21	6,468.27	5,840.96	13,619.48	11,557.89	23,284.68
	Total expenses	**16,952.46**	**15,664.11**	**13,766.73**	**32,616.57**	**26,976.85**	**55,514.89**
3	**Profit before tax [1 - 2]**	**7,792.65**	**7,091.61**	**5,746.72**	**14,884.26**	**10,999.51**	**23,788.35**
4	**Tax expense**						
	(a) Current tax	1,943.00	1,657.34	1,258.15	3,600.34	2,417.78	5,060.45
	(b) Deferred tax	57.19	119.51	190.77	176.70	378.91	799.71
	Total tax expense	**2,000.19**	**1,776.85**	**1,448.92**	**3,777.04**	**2,796.69**	**5,860.16**
5	**Profit for the period/year [3 - 4]**	**5,792.46**	**5,314.76**	**4,297.80**	**11,107.22**	**8,202.82**	**17,928.19**
6	**Other comprehensive income**						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit obligations	62.24	22.88	39.50	85.12	29.92	83.21
	(b) Income-tax relating to above item	(15.66)	(5.76)	(9.94)	(21.42)	(7.53)	(20.94)
	Other comprehensive income for the period/year (net of tax)	**46.58**	**17.12**	**29.56**	**63.70**	**22.39**	**62.27**
7	**Total comprehensive income for the period/year [5 + 6]**	**5,839.04**	**5,331.88**	**4,327.36**	**11,170.92**	**8,225.21**	**17,990.46**
8	**Paid-up equity share capital (Face value of Re. 1 each)**	1,029.98	1,028.97	1,027.25	1,029.98	1,027.25	1,028.97
9	**Other equity (Refer Note 6)**						93,408.32
10	**Earnings per equity share (Face value of Re. 1 each fully paid up)**	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	5.63	5.17	4.18	10.79	7.98	17.43
	- Diluted (in Rs.)	5.61	5.15	4.17	10.77	7.96	17.40

Notes:

1. The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 03 Nov 2026.The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2026. An unmodified report has been issued by them thereon.

3. The Company has one operating segment, namely "Diagnostic services" and the information reported to the Chief Operating Decision Maker (CODM) for the purposes of resource allocation and assessment of performance focuses on this operating segment. The Company has disclosed the segment information in the consolidated financial results.

4. During the quarter and year-to-date ended 30 September 2026, the Company has issued 100,987 equity shares of face value of Re. 1/- each on exercise of employee stock options.

5. During the year-to-date ended 30 September 2026, the Company has granted 269,500 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meetings held on 07 May 2026 and 09 July 2026.

6. The Board of Directors of the Company, at its meeting held on 07 May 2026, approved the acquisition of the business of Medinova Millennium MRI Services LLP ("Transferor Entity"), which is 100% owned by the Company, by way of a slump sale. The transaction has been accounted for in accordance with the pooling of interest method prescribed under Appendix C, Business Combinations of Entities Under Common Control, of Ind AS 103, Business Combinations. Accordingly, the assets, liabilities, reserves and surplus of the Transferor Entity have been recorded by the Company at their existing carrying amounts as appearing in the financial statements of the Transferor Entity after alignment of accounting policies, as applicable. The comparative financial information presented has been restated as if the business combination had occurred from the beginning of the preceding reporting period.
In giving effect to the transaction:
(a) All assets, liabilities, reserves and surplus of the Transferor Entity have been transferred to and vested in Vijaya Diagnostic Centre Limited ("the Company").
(b) The difference between the carrying value of the investment derecognised in the books of the Company and the net assets acquired and reserves and surplus of the Transferor entity has been recognised within Other Equity as "Common control acquisition deficit account".

7. The Board of Directors at its meeting held on 07 May 2026, had proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2025-26, subject to the approval of the members at the ensuing annual general meeting. The same was approved by the shareholders in the Annual General Meeting of the Company held on 24 September 2026 and was paid on 07 October 2026.

8. The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Kolkata
Date: 03 November 2026

VIJAYA DIAGNOSTIC CENTRE

Vijaya Diagnsotic Centre Limited

Statement of standalone unaudited assets and liabilities

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited (Refer Note 6)
	ASSETS		
I	**Non-current assets**		
	(a) Property, plant and equipment	55,563.94	51,627.02
	(b) Capital work-in-progress	3,283.21	3,424.01
	(c) Right-of-use assets	42,217.84	34,210.96
	(d) Other intangible assets	442.60	454.67
	(e) Intangible assets under development	100.77	78.65
	(f) Financial assets		
	(i) Investments	13,968.00	13,968.00
	(ii) Loans	2,424.00	2,709.00
	(iii) Other financial assets	1,937.64	4,579.79
	(g) Other non-current assets	4,031.35	3,082.22
	Total non-current assets	**123,969.35**	**114,134.32**
II	**Current assets**		
	(a) Inventories	791.15	445.96
	(b) Financial assets		
	(i) Investments	30,400.57	22,838.00
	(ii) Trade receivables	1,916.84	2,112.65
	(iii) Cash and cash equivalents	870.49	3,795.36
	(iv) Bank balances other than (iii) above	3,459.07	1,305.96
	(v) Other financial assets	6,796.01	801.05
	(c) Other current assets	662.84	682.02
	Total current assets	**44,896.97**	**31,981.00**
	TOTAL ASSETS (I + II)	**168,866.32**	**146,115.32**
	EQUITY AND LIABILITIES		
I	**Equity**		
	(a) Equity share capital	1,029.98	1,028.97
	(b) Other equity	103,262.11	93,408.32
	Total equity	**104,292.09**	**94,437.29**
	Liabilities		
II	**Non-current liabilities**		
	(a) Financial liabilities		
	(i) Lease liabilities	46,679.50	37,805.95
	(b) Provisions	1,141.02	1,051.52
	(c) Deferred tax liabilities (net)	1,534.48	1,336.35
	(d) Other non-current liabilities	55.01	46.60
	Total non-current liabilities	**49,410.01**	**40,240.42**
III	**Current liabilities**		
	(a) Financial liabilities		
	(i) Lease liabilities	1,773.83	1,816.89
	(ii) Trade payables		
	- Total outstanding dues of micro enterprises and small enterprises; and	115.32	256.82
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	3,829.07	3,233.63
	(iii) Other financial liabilities	7,337.99	4,747.13
	(b) Other current liabilities	642.71	489.18
	(c) Provisions	808.53	799.75
	(d) Current tax liabilities (net)	656.77	94.21
	Total current liabilities	**15,164.22**	**11,437.61**
	Total liabilities (II + III)	**64,574.23**	**51,678.03**
	TOTAL EQUITY AND LIABILITIES (I + II + III)	**168,866.32**	**146,115.32**

for and on behalf of the Board of Directors of

Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY

Digitally signed by SUPRITA SURA REDDY

S Suprita Reddy

Managing Director & CEO

DIN Number: 00263618

Place: Kolkata

Date: 03 November 2026

VIJAYA DIAGNOSTIC CENTRE

Vijaya Diagnsotic Centre Limited
Statement of standalone unaudited cash flows

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	For the period ended 30 September 2026	For the period ended 30 September 2025
		Unaudited	Unaudited (Refer Note 6)
(A)	**Cash flows from operating activities**		
	Profit before tax	**14,884.26**	**10,999.51**
	Adjustments for:		
	Depreciation and amortisation expense	4,631.53	3,775.92
	Net gain on sale/retirement of property, plant and equipment	(5.60)	(2.59)
	Interest income under the effective interest method	(455.82)	(421.46)
	Profit on sale of mutual fund investments (net)	(431.23)	(420.61)
	Fair value gain on investments measured at FVTPL	(544.62)	(345.21)
	Loss allowance for trade receivables	60.00	20.00
	Equity-settled share-based payment transactions (ESOP)	271.55	118.06
	Finance costs	2,030.57	1,322.08
	Liabilities no longer required written back	(1.37)	(0.77)
	Operating profit before working capital adjustments	**20,439.27**	**15,044.93**
	Working capital adjustments:		
	Decrease in trade receivables	135.81	142.29
	(Increase) / Decrease in inventories	(345.19)	59.19
	Decrease / (Increase) in other financial assets	102.51	(6.47)
	(Increase) in other assets and deposits	(896.00)	(966.31)
	Increase in trade payables	455.31	736.52
	Increase in provisions and other liabilities	313.84	291.49
	Increase in other financial liabilities	160.99	71.89
	Cash generated from operating activities	**20,366.54**	**15,373.53**
	Income tax paid, net	(3,037.78)	(2,089.64)
	Net cash generated from operating activities	**17,328.76**	**13,283.89**
(B)	**Cash flows from investing activities**		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other intangible assets and intangible assets under development (including capital advances and capital creditors)	(6,729.80)	(7,774.00)
	Proceeds from sale of property, plant and equipment	15.48	4.27
	Investment in liquid mutual funds/bonds, net	(6,586.72)	(3,641.60)
	Deposits made having original maturity of more than 3 months	(4,519.00)	(1,730.29)
	Deposits redeemed having original maturity of more than 3 months	1,434.03	5,821.98
	Loans given to subsidiaries	(150.00)	(1,373.00)
	Loans repaid by subsidiaries	435.00	70.00
	Interest received on deposits having original maturity of more than 3 months	98.22	332.69
	Interest received on loans given to subsidiaries	110.50	91.44
	Net cash used in investing activities	**(15,892.29)**	**(8,198.51)**
(C)	**Cash flows from financing activities**		
	Proceeds from the exercise of employee stock options	472.28	319.89
	Dividend paid	-	(2,054.55)
	Transfer to earmarked bank account for payment of dividend*	(2,059.95)	-
	Principal payment of lease liabilities	(746.96)	(985.32)
	Finance costs paid	(2,026.71)	(1,289.74)
	Net cash used in financing activities	**(4,361.34)**	**(4,009.72)**
	*Represents amounts transferred to an earmarked bank account for payment of dividend relating to FY 2025-26, which was subsequently paid on 07 October 2026.		
	Net increase/(decrease) in cash and cash equivalents (A + B + C)	**(2,924.87)**	**1,075.66**
	Cash and cash equivalents at the beginning of the period	3,795.36	1,187.45
	Cash and cash equivalents at the end of the period	**870.49**	**2,263.11**
	Cash and cash equivalents as per above comprise of the following:		
	Particulars	**As at 30 September 2026**	**As at 30 September 2025**
	Cash on hand	68.07	59.58
	Balances in wallets	15.02	-
	Balances with banks		
	- in current accounts	787.40	0.86
	- in deposit accounts having maturity less than three months	-	2,202.67
	Total cash and cash equivalents	**870.49**	**2,263.11**

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY
S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Kolkata
Date: 03 November 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

   Parent
   a. Vijaya Diagnostic Centre Limited

   Subsidiaries
   b. VDC Diagnostic (Karnataka) LLP
   c. Medinova Millenium MRI Services LLP
   d. P H Diagnostic Centre Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report *(Continued)*

Vijaya Diagnostic Centre Limited

6. We did not review the interim financial information of one subsidiary included in the Statement, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 7,363.02 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 1,380.12 lakhs and Rs. 2,660.82 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 190.53 lakhs and Rs. 218.28 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 202.30 lakhs and Rs. 230.81 lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and net decrease in cash flows (before consolidation adjustments) of Rs. 39.61 lakhs for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. These interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHAN KABRA

Digitally signed by BALKISHAN KABRA
Date: 2026.11.03 19:24:48 +05'30'

Balkishan Kabra

Partner

Membership No.: 221202

UDIN:26221202IHCJUJ3484

Hyderabad

03 November 2026

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075
Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and year-to-date ended 30 September 2026

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue from operations	25,538.72	23,098.19	20,156.18	48,636.91	38,961.49	81,420.19
	(b) Other income	495.10	853.03	624.86	1,348.13	1,329.70	2,079.92
	Total income	**26,033.82**	**23,951.22**	**20,781.04**	**49,985.04**	**40,291.19**	**83,500.11**
2	**Expenses**						
	(a) Cost of materials consumed	2,826.38	2,559.62	2,431.93	5,386.00	4,573.20	9,468.44
	(b) Employee benefits expense	3,834.66	3,747.56	3,225.93	7,582.22	6,386.64	13,073.76
	(c) Finance costs	1,137.94	1,100.32	782.72	2,238.26	1,531.26	3,323.09
	(d) Depreciation and amortisation expense	2,690.19	2,512.23	2,226.70	5,202.42	4,315.71	9,182.44
	(e) Other expenses	7,603.00	6,937.04	6,315.63	14,540.04	12,465.59	25,184.49
	Total expenses	**18,092.17**	**16,856.77**	**14,982.91**	**34,948.94**	**29,272.40**	**60,232.22**
3	**Profit before tax [1 - 2]**	**7,941.65**	**7,094.45**	**5,798.13**	**15,036.10**	**11,018.79**	**23,267.89**
4	**Tax expense**						
	(a) Current tax	1,943.00	1,657.34	1,263.15	3,600.34	2,422.78	5,067.73
	(b) Deferred tax, net	51.30	127.00	206.68	178.30	408.81	902.50
	Total tax expense	**1,994.30**	**1,784.34**	**1,469.83**	**3,778.64**	**2,831.59**	**5,970.23**
5	**Profit for the period/year [3 - 4]**	**5,947.35**	**5,310.11**	**4,328.30**	**11,257.46**	**8,187.20**	**17,297.66**
6	**Other comprehensive income**						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit obligations	77.98	23.89	39.50	101.87	29.92	86.89
	(b) Income-tax relating to above item	(19.63)	(6.01)	(9.94)	(25.64)	(7.53)	(21.87)
	Other comprehensive income for the period/year (net of tax)	**58.35**	**17.88**	**29.56**	**76.23**	**22.39**	**65.02**
7	**Total comprehensive income for the period/year [5 + 6]**	**6,005.70**	**5,327.99**	**4,357.86**	**11,333.69**	**8,209.59**	**17,362.68**
8	**Paid-up equity share capital (Face value of Re. 1 each)**	1,029.98	1,028.97	1,027.25	1,029.98	1,027.25	1,028.97
9	**Other equity**						94,686.21
10	**Earnings per equity share (Face value of Re. 1 each fully paid up)**	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	5.78	5.16	4.21	10.94	7.96	16.81
	- Diluted (in Rs.)	5.76	5.15	4.20	10.91	7.95	16.79

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).

2. The above consolidated financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 03, 2026. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2026. An unmodified report has been issued by them thereon.

3. The Group has one operating segment , namely "Diagnostic services" and the information reported to the Chief Operating Decision Maker (CODM) for the purpose of resource allocation and assessment of performance focuses on this operating segment.

(Rs. in Lakhs)

Particulars	For the Three Months ended / As at			Year-to-date ended / As at		For the Year ended / As at
	30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Segment Revenue: Revenue from operations	25,538.72	23,098.19	20,156.18	48,636.91	38,961.49	81,420.19
B. Segment Results: Profit before tax for the period/ year	7,941.65	7,094.45	5,798.13	15,036.10	11,018.79	23,267.89
C. Segment Assets: Total assets	173,334.95	167,693.18	139,070.14	173,334.95	139,070.14	150,704.83
D. Segment Liabilties: Total liabilities	67,602.20	66,490.37	52,562.86	67,602.20	52,562.86	54,989.65

Note: There are no unallocated corporate income / expense / asset and liabilities considering that the Group operates in a single segment.

4. During the quarter and year-to-dated ended 30 September 2026, the Company has issued 1,00,987 equity shares of face value of Re. 1/- each on exercise of employee stock options.

5. During the year-to-date ended 30 September 2026, the Company has granted 269,500 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meetings held on 07 May 2026 and 09 July 2026.

6. The Board of Directors at its meeting held on 07 May 2026, had proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2025-26, subject to the approval of the members at the ensuing annual general meeting. The same was approved by the shareholders in the Annual General Meeting of the Company held on 24 September 2026 and was paid on 07 October 2026.

7. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Kolkata
Date: 03 November 2026

Vijaya Diagnostic Centre Limited
Statement of consolidated unaudited assets and liabilities

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	As at 30 September 2026	As at 31 March 2026
		Unaudited	Audited
	ASSETS		
I	**Non-current assets**		
	(a) Property, plant and equipment	60,006.48	56,247.03
	(b) Capital work-in-progress	3,297.35	3,429.31
	(c) Right-of-use assets	44,452.07	36,715.35
	(d) Goodwill	11,920.49	11,920.49
	(e) Other intangible assets	1,997.17	2,044.15
	(f) Intangible assets under development	100.77	78.65
	(g) Financial assets		
	(i) Investments	4.00	4.00
	(ii) Other financial assets	2,363.98	4,808.58
	(h) Other tax assets, (net)	42.24	24.77
	(i) Other non-current assets	4,170.78	3,242.54
	Total non-current assets	**128,355.33**	**118,514.87**
II	**Current assets**		
	(a) Inventories	828.46	489.20
	(b) Financial assets		
	(i) Investments	30,400.57	22,838.00
	(ii) Trade receivables	1,793.93	2,086.02
	(iii) Cash and cash equivalents	1,007.87	3,967.52
	(iv) Bank balances other than (iii) above	3,459.07	1,305.96
	(v) Other financial assets	6,796.00	801.05
	(c) Other current assets	693.72	702.21
	Total current assets	**44,979.62**	**32,189.96**
	TOTAL ASSETS (I + II)	**173,334.95**	**150,704.83**
	EQUITY AND LIABILITIES		
I	**Equity**		
	(a) Equity share capital	1,029.98	1,028.97
	(b) Other equity	104,702.77	94,686.21
	Total equity	**105,732.75**	**95,715.18**
	Liabilities		
II	**Non-current liabilities**		
	(a) Financial liabilities		
	(i) Lease liabilities	48,622.89	40,002.77
	(b) Provisions	1,182.43	1,101.90
	(c) Deferred tax liabilities, (net)	1,655.89	1,451.94
	(d) Other non-current liabilities	55.01	46.60
	Total non-current liabilities	**51,516.22**	**42,603.21**
III	**Current liabilities**		
	(a) Financial liabilities		
	(i) Lease liabilities	2,251.99	2,255.73
	(ii) Trade payables		
	- Total outstanding dues of micro enterprises and small enterprises; and	127.31	279.71
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	4,089.82	3,476.59
	(iii) Other financial liabilities	7,443.72	4,914.07
	(b) Other current liabilities	683.35	534.16
	(c) Provisions	828.19	831.97
	(d) Current tax liabilities (net)	661.60	94.21
	Total current liabilities	**16,085.98**	**12,386.44**
	Total liabilities (II + III)	**67,602.20**	**54,989.65**
	TOTAL EQUITY AND LIABILITIES (I + II + III)	**173,334.95**	**150,704.83**

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY
S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Kolkata
Date: 03 November 2026

VIJAYA DIAGNOSTIC CENTRE

Vijaya Diagnostic Centre Limited
Statement of consolidated unaudited cash flows

(Rs. in Lakhs except as stated)

Sl.No	Particulars	For the period ended 30 September 2026	For the period ended 30 September 2025
		Unaudited	Unaudited
A.	**Cash flow from operating activities**		
	Profit before tax	**15,036.10**	**11,018.79**
	Adjustments for:		
	Depreciation and amortisation expense	5,202.42	4,315.71
	Net gain on sale/ retirement of property, plant and equipment	(5.60)	(153.03)
	Interest income under the effective interest method	(354.65)	(355.50)
	Profit on sale of mutual fund investments, (net)	(431.23)	(420.61)
	Loss allowance for trade receivables	65.00	80.00
	Equity-settled share based payment transactions (ESOP)	271.55	118.06
	Fair value gain on investments measured at FVTPL	(544.62)	(345.21)
	Finance costs	2,138.82	1,531.26
	Liabilities no longer required, written back	(1.39)	(0.77)
	Operating profit before working capital changes	**21,376.40**	**15,788.70**
	Working capital adjustments:		
	Decrease in trade receivables	227.09	201.08
	(Increase) / Decrease in inventories	(339.26)	135.06
	Decrease / (Increase) in other financial assets	102.51	(129.67)
	(Increase) in other assets and deposits	(1,077.36)	(1,073.12)
	Increase in trade payables	462.22	668.18
	Increase in provisions and other liabilities	304.73	304.13
	Increase in other financial liabilities	170.44	78.38
	Cash generated from operations	**21,226.77**	**15,972.74**
	Income tax paid, net	(3,050.42)	(2,107.48)
	Net cash generated from operating activities	**18,176.35**	**13,865.26**
B.	**Cash flows from investing activities**		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other Intangible assets and intangible assets under development (including capital advances and capital creditors)	(6,893.35)	(9,334.95)
	Proceeds from sale of property, plant and equipment	18.51	156.06
	Investment in liquid mutual funds/bonds, net	(6,586.72)	(3,641.59)
	Deposits made having original maturity of more than 3 months	(4,523.00)	(1,770.30)
	Deposits redeemed having original maturity of more than 3 months	1,434.02	5,821.98
	Interest received	98.23	366.39
	Net cash used in investing activities	**(16,452.31)**	**(8,402.41)**
C.	**Cash flows from financing activities**		
	Proceeds from the exercise of employee stock options	472.28	319.89
	Dividend paid	-	(2,054.51)
	Transfer to earmarked bank account for payment of dividend*	(2,059.95)	-
	Principal payment of lease liabilities	(961.06)	(1,186.79)
	Finance costs paid	(2,134.96)	(1,400.87)
	Net cash used in financing activities	**(4,683.69)**	**(4,322.28)**
	*Represents amounts transferred to an earmarked bank account for payment of dividend relating to FY 2025-26, which was subsequently paid on 07 October 2026.		
	Net increase / (decrease) in cash and cash equivalents (A + B + C)	**(2,959.65)**	**1,140.57**
	Cash and cash equivalents at the beginning of the period	3,967.52	1,280.11
	Cash and cash equivalents at end of the period	**1,007.87**	**2,420.68**
	Cash and cash equivalents as per above comprise of the following:		
	Particulars	**As at 30 September 2026**	**As at 30 September 2025**
	Cash on hand	70.61	62.83
	Balances in wallets	17.93	-
	Balances with banks		
	- in current accounts	919.33	2,356.99
	- in deposit accounts having maturity less than three months	-	0.86
	Total cash and cash equivalents	**1,007.87**	**2,420.68**

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited
SUPRITA SURA REDDY
Digitally signed by SUPRITA SURA REDDY
S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Kolkata
Date: 03 November 2026